Biotech Short Candidates Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tuck	10/3/2005 12:53:39 PM
	Read Replies (1) of 897

Trimeris is bumping up these days. The uptrend seemed to begin after Glaxo started seeing liver toxicity issues with its CCR5 inhibitor -- considered an entry inhibitor as is TRMS' Fuzeon. A minor amendment to the manufacturing agreement with Roche has transpired. Meanwhile cash dwindles and financing seems imminent. Insider activity is mixed. I'm very tempted to short here. Anyone else got thoughts? Chart: stockcharts.com[m,a]daclyyay[pb50!b200][vc60][iub14!lh7,10]&r=0667 Looks overbought to me. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next